Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study.

“I wasn't surprised by the result.” Call it the Joao Factor. Fonseca only fed that frenzy in his press conference. “When I arrived here, my first goal was to qualify for the main draw,” he ...

Haemophilia is a hereditary blood disorder characterized by a deficiency of certain coagulation factors, which can lead to life-threatening bleeding if left untreated. Why haemophilia A (with ...

A study published in Nature Cardiovascular Research identifies an intrinsic anti-inflammatory factor that can be therapeutically targeted to reduce vascular inflammation and atherosclerosis.